Today, 20 June 2013, the Department of Health
has announced new developments in the
process of designing and implementing the new value-based system of
drug pricing. These include the fact that the National
Institute for Health and Care Excellence will now be consulting
various stakeholders including patient groups in the process of
allocating value to different drugs.
Owen Sharp, Chief Executive of Prostate Cancer UK said: "For far
too long, lack of clarity on how value-based
pricing will work has prevented us and other patient groups
from engaging with its development. Although today's announcement
sheds an encouraging chink of light, there is still much more
that needs to be clarified, and many more areas where patient
opinion is crucial to building a system fit for purpose.
"We hope that today's declaration signals a change of tack from
the Department of Health and that much more will be unveiled over
the coming weeks, including a firmer commitment to involving
patient groups in a purposeful way and on a continuing basis.
Otherwise we will remain concerned that the Department risks
undermining the credibility and effectiveness of the new system
before it has even been established."